CAIRO PHARMACEUTICALS
CPCI

EGX

Current Price
EGP
EGP (%)
Price Upon Recommendation
166.16 EGP
Target Price from Recommendation

188.50 EGP

+13.70%
Holding Period

From 6 to 12 months

Final Recommendation

Buy stock at the current price

Valid Until

October 15, 2025 at 11:59:59 PM

Risk Assessment

Medium

Confidence Score

85.00%

Potential Growth

18.50%

Investment Reason

CPCI demonstrates strong fundamentals and aligns with Egypt's growing industrial and financial sectors, supported by its inclusion in top-performing EGX indices. Recent market resilience and strategic positioning in high-demand industries enhance its growth potential.

Overview
Recent Performance

CPCI has shown consistent upward momentum, with a 12.4% YTD gain, outperforming the EGX30 index. Recent highs of 169.68 EGP reflect strong investor confidence.

Economic Factors

Egypt's economic reforms, rising interest rates, and IMF partnerships stabilize the macroeconomic environment. Sector-specific growth in banking and infrastructure bolsters CPCI's outlook.

Competitive Positioning

CPCI holds a strategic position in Egypt's financial sector, leveraging its diversified portfolio and strong balance sheet. It benefits from regulatory support and increasing foreign investment inflows.

Analysis Summary

CPCI's strong financials, sector leadership, and alignment with Egypt's growth trajectory make it a compelling buy. Target price reflects anticipated market expansion and dividend stability.

Key Points
  • Strong alignment with Egypt's top-performing EGX indices
  • 12.4% YTD gain with consistent upward momentum
  • Strategic diversification in high-growth financial sectors
  • IMF-backed economic reforms enhancing macro stability
Recommendations